Expression of immune checkpoint PD-1 in non-small cell lung cancer is associated with tumor cell DNA-dependent protein kinase

Immunotherapy using immune checkpoint inhibitors has demonstrated durable responses and has significantly improved survival in patients with non-small cell lung cancer (NSCLC). Moreover, immunotherapy is increasingly used in combination with cytotoxic treatments such as chemotherapy and radiotherapy...

Descripción completa

Detalles Bibliográficos
Autores principales: Saar, Marika, Narits, Jaanika, Mägi, Laura, Aaspõllu, Hardi, Vapper, Annett, Kase, Marju, Minajeva, Ave, Vooder, Tõnu, Tamm, Hannes, Buldakov, Maksim, Lavõgina, Darja, Jaal, Jana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2021
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8375025/
https://www.ncbi.nlm.nih.gov/pubmed/34462666
http://dx.doi.org/10.3892/mco.2021.2369

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8375025/
https://www.ncbi.nlm.nih.gov/pubmed/34462666
http://dx.doi.org/10.3892/mco.2021.2369

Ejemplares similares